Abingworth, a global life sciences investment firm, closed its new Clinical Co-Development Co-Investment Fund, at $356M.
CCD-CIF received support from Abingworth’s existing investor base and added new investors from the US and Europe.
Abingworth started the clinical co-development (CCD) investment strategy in 2009, investing initially via its venture funds and then through its first dedicated fund, Abingworth Clinical Co-Development Fund (ACCD 1), which launched in 2016 raising $109M. To date, Abingworth has made 14 investments in CCD opportunities, working with partners such as AstraZeneca, Eisai, Apellis, and Pfizer.
Alongside the Abingworth Clinical Co-Development Fund 2 (ACCD 2), a fund of $583M, Abingworth has raised over $930M in new funds since 2021 to invest in the development of late-stage clinical programs from pharmaceutical and biotechnology companies in the US, UK, Europe, and Asia-Pacific.
Based in London, UK-, Menlo Park, CA- and Boston, MA, Abingworth is a life sciences investment firm offering capital and expertise to management teams building companies. Its therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Since 1973, Abingworth has invested in over 185 life science companies, leading to 49 M&As and 75 IPOs.
Abingworth is part of global investment firm Carlyle (NASDAQ: CG).
FinSMEs
30/10/2023